Enteral probiotics such as Lactobacillus casei GG (LGG) have been used in t
he treatment of a variety of intestinal disorders in infants and children,
including diarrhea, malabsorption, and Clostridium difficile colitis. We ha
ve previously demonstrated that the probiotic bacterium LGG has an inhibito
ry effect on bacterial translocation (BT) in a neonatal rabbit model. Howev
er, this in-vivo model is limited for investigating the cellular and molecu
lar mechanisms responsible for probiotic inhibition of BT. The purpose of t
his study was to determine the efficacy of LGG in reducing the rate of Esch
erichia coli C25 (E. coli C25) translocation using an in-vitro enterocyte c
ell-culture model. Human colonic carcinoma (Caco-2) enterocytes were seeded
in porous filters in the apical chamber of a two-chamber cell-culture syst
em and grown for 14 days to confluence. The monolayers were incubated at 37
degreesC with LGG for 180 min. Non-adherent LGG was washed away prior to a
120-min incubation period with 10(5) CFU E. coli C25. E. coli that had tra
nslocated across the enterocyte monolayer were quantified by growing basal-
chamber media samples on gram-negative bacteria-specific MacConkey's agar.
In order to determine monolayer integrity, transepithelial electrical resis
tance (TEER) was measured across Caco-2 cells treated with LGG and E. coli.
Statistical analysis was by ANOVA with P < 0.05 considered significant. LG
G inhibited E. coli translocation at all LGG concentrations tested. The TEE
R ratio was not significantly altered by addition of LGG or E, coli (0.9 +/
- 0.03 vs 0.8 +/- 0.05). These results demonstrate that the probiotic bacte
rium LGG inhibits BT of E. coli C25 in a dose-dependent manner in an invitr
o cell-culture model. This model should be valuable in investigating the ce
llular and molecular mechanisms involved in the inhibition of pathological
enteral bacteria by probiotic agents.